Wegovy HD: is 7.2 mg worth it, and what changes from 2.4 mg

Reviewed 6 sourcesPublished by PepVault

Wegovy HD 7.2 mg against 2.4 mg in the STEP UP trials: the extra weight lost, who reached 20% and 25%, the side effects side by side, and who the label allows.

Grey-bearded man in tennis whites hits a forehand with a wooden racket on a clay court
Last reviewed
Sources
6
Questions
7
Compounds
1

The short answer

As of November 20, 2026, Wegovy HD (7.2 mg weekly) is for adults who have tolerated 2.4 mg for at least four weeks and whose prescriber judges they need more weight loss. In the 72-week STEP UP trial it averaged an 18.8% loss against 15.5% on 2.4 mg, and 45.5% lost a fifth of their weight against 32.3%. The trade: more vomiting, and skin-sensation changes (22% against 6%, both trials).

Every number checked at its primary source · · 6 sources · How we research

Evidence: Two randomised, double-blind 72-week phase 3b trials in 1,919 adults with obesity, with and without type 2 diabetes (STEP UP and STEP UP T2D, both funded by Novo Nordisk), and the FDA label and approval built on them; the 7.2 mg dose is FDA-approved.

Grey-bearded man in tennis whites hits a forehand with a wooden racket on a clay court

How much more weight do you lose on 7.2 mg than on 2.4 mg?

About three more points of body weight on average, and a much bigger share of people at the top end. STEP UP randomised 1,407 adults with obesity and no diabetes to 7.2 mg, 2.4 mg or placebo for 72 weeks; at the end, 7.2 mg was ahead of 2.4 mg by 3.3 percentage points, a gap that held up statistically13. For someone starting at 250 pounds, 3.3 points is about 8 pounds. The average undersells the dose, though: the clearer change is how many people reached the big milestones.

At week 72PlaceboWegovy 2.4 mgWegovy HD 7.2 mg
Average weight change−3.9%1−15.5%1−18.8%1
Lost 5% or more38.3%186.6%188.7%1
Lost 10% or more20.3%172%179.8%1
Lost 15% or more7.5%152.3%163.8%1
Lost 20% or more2.8%132.3%145.5%1
Lost 25% or more (trial registry: only people weighed at week 72)0 of 171515.3% (29 of 189)531.2% (296 of 950)5
Waist change−5.6 cm1−14.2 cm1−17.5 cm1

Read the table from the bottom up. Almost everyone on either dose lost 5%, so at that line the extra drug adds little. The doses pull apart at 20% and 25%: twice as many people on 7.2 mg lost a quarter of their body weight5. The label's rows count everyone randomised, including people who stopped the drug; the 25% row comes from the trial's posted results and counts only those weighed at week 72, so its percentages run a little higher15. These are group results, not a forecast for one person.

PepVault's weigh-in log draws your trend in pounds or kilograms, so the weeks on 2.4 mg and any weeks after a change read side by side. Track your weight in PepVault

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

PepVault for iPhone

Keep your protocol in PepVault

PepVault's weigh-in log draws your trend in pounds or kilograms, so the weeks on 2.4 mg and any weeks after a change read side by side.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What changes in your body when the dose goes up to 7.2 mg?

Three times the drug in your blood. At steady state, the level reached once each weekly dose balances what the body clears, semaglutide averaged about 75 nmol/L on 2.4 mg and about 230 nmol/L on 7.2 mg, and the label says exposure rose in proportion to the dose all the way up1. Semaglutide is a GLP-1 receptor agonist: it copies a gut hormone that slows the stomach and quiets hunger signals in the brain, so more of it at the receptor means more of that effect, and more of its side effects.

The step itself is a single jump. Wegovy HD is one 7.2 mg single-dose pen of 0.75 mL, and the label lists no strength between 2.4 mg and 7.2 mg1. In both trials the 7.2 mg group climbed the usual ladder, 0.25, 0.5, 1, 1.7 and 2.4 mg, four weeks each, then went to 7.2 mg at week 2056. With a half-life of about a week, each dose stacks on the last, so the new level builds over the following weeks rather than on the day of the step1. The chart shows the build.

Try it

How Semaglutide builds up

An estimate from a half-life of about 6.9 days, one dose a week for four weeks. The shape of the level, not a measurement.

Try your own scheduleSemaglutide in the library

Which side effects go up at 7.2 mg?

Mostly the same stomach effects as 2.4 mg, a little more often, plus one effect that clearly rises. The label pooled the two trials and listed the effects more common on 7.2 mg than on both 2.4 mg and placebo1:

Effect (both trials pooled)PlaceboWegovy 2.4 mgWegovy HD 7.2 mg
Nausea13%135%139%1
Vomiting6%116%122%1
Dysesthesia (altered skin sensation)0%16%122%1
Constipation8%119%120%1
Belly pain7%19%112%1
Tiredness5%19%111%1
Hair loss1%13%16%1
Stopped for a side effect2%15%15%1

The bottom row is the one people underrate: the share who quit because of side effects was the same on both doses, 5%, and stomach effects made up 3 points of it in each1. Serious adverse events in STEP UP were 6.8% on 7.2 mg, 10.9% on 2.4 mg and 5.5% on placebo3. Hair loss nearly doubled, and it fell almost entirely on women: 8.4% of women on 7.2 mg against 5.4% on 2.4 mg, and 0.2% of men1. The semaglutide side-effects page and our Ozempic and Wegovy side-effects guide cover what helps with each stomach effect.

Commonly reported: a few days of stronger nausea or fullness after the first 7.2 mg pens, settling over the following weeks, and skin that feels sore, prickly or sunburnt on 7.2 mg.

When to get help Belly pain that is severe and will not go away, with or without vomiting, is the label's reason to stop Wegovy and call your prescriber right away1.

What is dysesthesia on Wegovy, and does it go away?

Dysesthesia is skin that feels wrong: tingling, burning, prickling, or touch that hurts more than it should. The label groups pins and needles, skin pain, sensitive skin and burning skin under the term, and says it grew with the dose and with the drug level in the blood1. It is the one side effect that sets 7.2 mg apart: 22% on 7.2 mg, 6% on 2.4 mg and 0.3% on placebo across the two trials1.

Most of it resolved, usually after the dose was paused or lowered; the side-effects guide has the full count1. What matters for the step: of 38 people who recovered and then went back up to 7.2 mg, 17 (45%) had it again1. The FDA's approval letter requires Novo Nordisk to track dysesthesia as a named safety event, case by case, in a further trial of 7.2 mg against 2.4 mg2.

PepVault's side-effect log records each symptom with its date and severity, including one you name yourself, such as skin tingling, so its pattern after each dose is there to show your prescriber. Log it in PepVault

Does 7.2 mg work as well if you have type 2 diabetes?

It works, from a lower starting point. STEP UP T2D randomised 512 adults with obesity and type 2 diabetes (HbA1c 7 to 10%) for 72 weeks4. Weight fell 13.2% on 7.2 mg, 10.4% on 2.4 mg and 3.8% on placebo; 20.6% lost a fifth of their weight on 7.2 mg against 13.5% on 2.4 mg1. The label marks the 2.4 mg results in this trial as informative only, because the trial was built to test 7.2 mg against placebo14.

Blood sugar barely separated the doses: HbA1c, the three-month sugar average, fell 1.7 points on 7.2 mg and 1.6 on 2.4 mg1. Stomach effects were close too, 53.1% against 51.5%, and the authors judged the two doses alike in tolerability apart from dysesthesia, 18.9% against 4.9%4. Low blood sugar of the serious kinds was rare and similar across the three groups4.

Who can be prescribed Wegovy HD?

The FDA approved the 7.2 mg dose on March 19, 2026, as a new dose for weight reduction and keeping it off long term2. As of November 20, 2026, the label's rules are these1:

  • Adults only. Safety and effectiveness of 7.2 mg are not established in children; the FDA has required trials in 6- to 17-year-olds who still need weight loss after 2.4 mg12.
  • After 2.4 mg, not instead of it: for people who tolerate 2.4 mg for at least four weeks and for whom more weight reduction is clinically indicated1.
  • For weight, not the other uses. For heart-risk reduction the maintenance dose stays 2.4 mg or 1.7 mg, and 7.2 mg is not established for the liver disease MASH1.
  • Tested at a BMI of 30 or more. The 7.2 mg line sits under weight reduction in adults, an indication that also covers overweight with a weight-related condition, but both trials enrolled only adults with obesity134.

Whether to move from 2.4 mg to 7.2 mg is the prescriber's call; the label asks them to weigh treatment response and tolerability1. How to use the HD pen is in our guide to the Ozempic and Wegovy pens, the full dose ladder in Wegovy and Ozempic dosage, and the label at a glance at pepvault.app/drugs/wegovy.

Will 7.2 mg break a plateau on 2.4 mg?

No trial has tested that yet. STEP UP and STEP UP T2D assigned people to 7.2 mg or 2.4 mg on day one and climbed both groups the same way346; nobody was moved up because they had stalled. So the trials show that, for a group, the 7.2 mg dose ends 72 weeks lower than 2.4 mg. They do not show how much someone who has stopped losing on 2.4 mg will lose after the step. The label's wording, more weight reduction when clinically indicated in people who tolerate 2.4 mg, describes who may be moved up and leaves the judgement to the prescriber1.

What a prescriber weighs is mostly what you bring. These are the records that make the conversation short:

  1. Pull up your weight trend for the last 8 to 12 weeks on 2.4 mg, so the plateau is a line, not a feeling.
  2. List the side effects you have had on 2.4 mg, how often and how strong, since the label's test is that you tolerate 2.4 mg.
  3. Note any missed or late doses: after two or more missed in a row, the label restarts the climb lower, which can look like a stall1.
  4. Ask what the step changes for you: the trials' extra three points on average, a twice-as-likely 25% loss, and about one in five people with skin sensations15.

Why a plateau happens, and what the trials say about slow responders on every GLP-1, is in our guide on GLP-1s that seem not to work.

Track it in the app

Sources

  1. WEGOVY (semaglutide) injection and tablets prescribing information, DailyMed SPL version 19 (updated June 18, 2026; published June 30, 2026), read November 20, 2026 dailymed.nlm.nih.gov
  2. US FDA. Supplement approval letter, NDA 215256/S-029 and NDA 218316/S-005 (Wegovy injection 7.2 mg weekly dose), March 19, 2026 accessdata.fda.gov
  3. Wharton S et al.; STEP UP trial group. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963. PubMed 40961952
  4. Lingvay I et al.; STEP UP T2D trial group. Once-weekly semaglutide 7.2 mg in adults with obesity and type 2 diabetes (STEP UP T2D): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):935-948. PubMed 40961953
  5. ClinicalTrials.gov NCT05646706 (STEP UP), Novo Nordisk A/S: arms and posted results, read November 20, 2026 clinicaltrials.gov
  6. ClinicalTrials.gov NCT05649137 (STEP UP T2D), Novo Nordisk A/S: arms and posted results, read November 20, 2026 clinicaltrials.gov

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo